GNLX
Price:
$4.65
Market Cap:
$176.94M
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
Industry
Biotechnology
IPO Date
2023-01-26
Stock Exchange
NASDAQ
Ticker
GNLX
According to Genelux Corporation’s latest financial reports and current stock price. The company's current ROE is -129.29%. This represents a change of 288.19% compared to the average of -33.31% of the last 4 quarters.
The mean historical ROE of Genelux Corporation over the last ten years is -13.04%. The current -129.29% ROE has changed 891.86% with respect to the historical average. Over the past ten years (40 quarters), GNLX's ROE was at its highest in in the June 2021 quarter at 80.88%. The ROE was at its lowest in in the March 2023 quarter at -385.14%.
Average
-13.04%
Median
30.72%
Minimum
-145.31%
Maximum
65.61%
Discovering the peaks and valleys of Genelux Corporation ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 39.96%
Maximum Annual ROE = 65.61%
Minimum Annual Increase = -1098.61%
Minimum Annual ROE = -145.31%
| Year | ROE | Change |
|---|---|---|
| 2024 | -113.68% | -21.77% |
| 2023 | -145.31% | -1098.61% |
| 2022 | 14.55% | -72.92% |
| 2021 | 53.74% | -18.09% |
| 2020 | 65.61% | 39.96% |
The current ROE of Genelux Corporation (GNLX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-81.48%
5-year avg
-25.02%
10-year avg
-13.04%
Genelux Corporation’s ROE is greater than Aldeyra Therapeutics, Inc. (-73.63%), greater than Silence Therapeutics plc (-85.88%), greater than Alpha Tau Medical Ltd. (-56.45%), greater than Candel Therapeutics, Inc. (-14.76%), greater than AC Immune S.A. (-49.04%), greater than Mereo BioPharma Group plc (-80.00%), greater than Lyell Immunopharma, Inc. (-85.58%), greater than Cellectis S.A. (-49.81%), greater than Contineum Therapeutics, Inc. Class A Common Stock (-32.33%), greater than Lexeo Therapeutics, Inc. Common Stock (-94.65%),
| Company | ROE | Market cap |
|---|---|---|
| -73.63% | $293.49M | |
| -85.88% | $336.78M | |
| -56.45% | $346.14M | |
| -14.76% | $288.78M | |
| -49.04% | $289.73M | |
| -80.00% | $325.72M | |
| -85.58% | $540.20M | |
| -49.81% | $484.47M | |
| -32.33% | $320.40M | |
| -94.65% | $663.45M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Genelux Corporation using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Genelux Corporation or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Genelux Corporation's ROE?
How is the ROE calculated for Genelux Corporation (GNLX)?
What is the highest ROE for Genelux Corporation (GNLX)?
What is the 3-year average ROE for Genelux Corporation (GNLX)?
What is the 5-year average ROE for Genelux Corporation (GNLX)?
How does the current ROE for Genelux Corporation (GNLX) compare to its historical average?